TAK-220 is primarily researched for its potential application in the treatment of HIV. It functions as a CCR5 antagonist, which means it blocks the CCR5 receptor on the surface of immune cells. This receptor is a key entry point for certain strains of the HIV virus. By inhibiting CCR5, TAK-220 can prevent the virus from entering and infecting healthy cells, thereby slowing the progression of the disease. Its development is part of ongoing efforts to create more effective antiretroviral therapies, particularly for patients who may have developed resistance to other treatments. Studies continue to explore its efficacy, safety, and potential role in combination therapies for managing HIV infection.